Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi

Jodi McBride, Ryan L. Boudreau, Scott Q. Harper, Patrick D. Staber, Alex Mas Monteys, Inês Martins, Brian L. Gilmore, Haim Burstein, Richard W. Peluso, Barry Polisky, Barrie J. Carter, Beverly L. Davidson

Research output: Contribution to journalArticle

410 Citations (Scopus)

Abstract

Huntington's disease (HD) is a fatal, dominant neurodegenerative disease caused by a polyglutamine repeat expansion in exon 1 of the HD gene, which encodes the huntingtin protein. We and others have shown that RNAi is a candidate therapy for HD because expression of inhibitory RNAs targeting mutant human HD transgenes improved neuropathology and behavioral deficits in HD mouse models. Here, we developed shRNAs targeting conserved sequences in human HD and mouse HD homolog (HDh) mRNAs to initiate preclinical testing in a knockin mouse model of HD. We screened 35 shRNAs in vitro and subsequently narrowed our focus to three candidates for in vivo testing. Unexpectedly, two active shRNAs induced significant neurotoxicity in mouse striatum, although HDh mRNA expression was reduced to similar levels by all three. Additionally, a control shRNA containing mismatches also induced toxicity, although it did not reduce HDh mRNA expression. Interestingly, the toxic shRNAs generated higher antisense RNA levels, compared with the nontoxic shRNA. These results demonstrate that the robust levels of antisense RNAs emerging from shRNA expression systems can be problematic in the mouse brain. Importantly, when sequences that were toxic in the context of shRNAs were placed into artificial microRNA (miRNA) expression systems, molecular and neuropathological readouts of neurotoxicity were significantly attenuated without compromising mouse HDh silencing efficacy. Thus, miRNA-based approaches may provide more appropriate biological tools for expressing inhibitory RNAs in the brain, the implications of which are crucial to the development of RNAi for both basic biological and therapeutic applications.

Original languageEnglish (US)
Pages (from-to)5868-5873
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume105
Issue number15
DOIs
StatePublished - Apr 15 2008
Externally publishedYes

Fingerprint

Huntington Disease
MicroRNAs
Small Interfering RNA
Brain
Antisense RNA
Poisons
RNA Interference
Messenger RNA
RNA
RNAi Therapeutics
Conserved Sequence
Transgenes
Neurodegenerative Diseases
Exons
Therapeutics
Genes

Keywords

  • AAV
  • Gene therapy
  • Huntington's disease
  • RNAi

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Artificial miRNAs mitigate shRNA-mediated toxicity in the brain : Implications for the therapeutic development of RNAi. / McBride, Jodi; Boudreau, Ryan L.; Harper, Scott Q.; Staber, Patrick D.; Monteys, Alex Mas; Martins, Inês; Gilmore, Brian L.; Burstein, Haim; Peluso, Richard W.; Polisky, Barry; Carter, Barrie J.; Davidson, Beverly L.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, No. 15, 15.04.2008, p. 5868-5873.

Research output: Contribution to journalArticle

McBride, J, Boudreau, RL, Harper, SQ, Staber, PD, Monteys, AM, Martins, I, Gilmore, BL, Burstein, H, Peluso, RW, Polisky, B, Carter, BJ & Davidson, BL 2008, 'Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi', Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 15, pp. 5868-5873. https://doi.org/10.1073/pnas.0801775105
McBride, Jodi ; Boudreau, Ryan L. ; Harper, Scott Q. ; Staber, Patrick D. ; Monteys, Alex Mas ; Martins, Inês ; Gilmore, Brian L. ; Burstein, Haim ; Peluso, Richard W. ; Polisky, Barry ; Carter, Barrie J. ; Davidson, Beverly L. / Artificial miRNAs mitigate shRNA-mediated toxicity in the brain : Implications for the therapeutic development of RNAi. In: Proceedings of the National Academy of Sciences of the United States of America. 2008 ; Vol. 105, No. 15. pp. 5868-5873.
@article{1016beced1084f63af1d968ff6800028,
title = "Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi",
abstract = "Huntington's disease (HD) is a fatal, dominant neurodegenerative disease caused by a polyglutamine repeat expansion in exon 1 of the HD gene, which encodes the huntingtin protein. We and others have shown that RNAi is a candidate therapy for HD because expression of inhibitory RNAs targeting mutant human HD transgenes improved neuropathology and behavioral deficits in HD mouse models. Here, we developed shRNAs targeting conserved sequences in human HD and mouse HD homolog (HDh) mRNAs to initiate preclinical testing in a knockin mouse model of HD. We screened 35 shRNAs in vitro and subsequently narrowed our focus to three candidates for in vivo testing. Unexpectedly, two active shRNAs induced significant neurotoxicity in mouse striatum, although HDh mRNA expression was reduced to similar levels by all three. Additionally, a control shRNA containing mismatches also induced toxicity, although it did not reduce HDh mRNA expression. Interestingly, the toxic shRNAs generated higher antisense RNA levels, compared with the nontoxic shRNA. These results demonstrate that the robust levels of antisense RNAs emerging from shRNA expression systems can be problematic in the mouse brain. Importantly, when sequences that were toxic in the context of shRNAs were placed into artificial microRNA (miRNA) expression systems, molecular and neuropathological readouts of neurotoxicity were significantly attenuated without compromising mouse HDh silencing efficacy. Thus, miRNA-based approaches may provide more appropriate biological tools for expressing inhibitory RNAs in the brain, the implications of which are crucial to the development of RNAi for both basic biological and therapeutic applications.",
keywords = "AAV, Gene therapy, Huntington's disease, RNAi",
author = "Jodi McBride and Boudreau, {Ryan L.} and Harper, {Scott Q.} and Staber, {Patrick D.} and Monteys, {Alex Mas} and In{\^e}s Martins and Gilmore, {Brian L.} and Haim Burstein and Peluso, {Richard W.} and Barry Polisky and Carter, {Barrie J.} and Davidson, {Beverly L.}",
year = "2008",
month = "4",
day = "15",
doi = "10.1073/pnas.0801775105",
language = "English (US)",
volume = "105",
pages = "5868--5873",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "15",

}

TY - JOUR

T1 - Artificial miRNAs mitigate shRNA-mediated toxicity in the brain

T2 - Implications for the therapeutic development of RNAi

AU - McBride, Jodi

AU - Boudreau, Ryan L.

AU - Harper, Scott Q.

AU - Staber, Patrick D.

AU - Monteys, Alex Mas

AU - Martins, Inês

AU - Gilmore, Brian L.

AU - Burstein, Haim

AU - Peluso, Richard W.

AU - Polisky, Barry

AU - Carter, Barrie J.

AU - Davidson, Beverly L.

PY - 2008/4/15

Y1 - 2008/4/15

N2 - Huntington's disease (HD) is a fatal, dominant neurodegenerative disease caused by a polyglutamine repeat expansion in exon 1 of the HD gene, which encodes the huntingtin protein. We and others have shown that RNAi is a candidate therapy for HD because expression of inhibitory RNAs targeting mutant human HD transgenes improved neuropathology and behavioral deficits in HD mouse models. Here, we developed shRNAs targeting conserved sequences in human HD and mouse HD homolog (HDh) mRNAs to initiate preclinical testing in a knockin mouse model of HD. We screened 35 shRNAs in vitro and subsequently narrowed our focus to three candidates for in vivo testing. Unexpectedly, two active shRNAs induced significant neurotoxicity in mouse striatum, although HDh mRNA expression was reduced to similar levels by all three. Additionally, a control shRNA containing mismatches also induced toxicity, although it did not reduce HDh mRNA expression. Interestingly, the toxic shRNAs generated higher antisense RNA levels, compared with the nontoxic shRNA. These results demonstrate that the robust levels of antisense RNAs emerging from shRNA expression systems can be problematic in the mouse brain. Importantly, when sequences that were toxic in the context of shRNAs were placed into artificial microRNA (miRNA) expression systems, molecular and neuropathological readouts of neurotoxicity were significantly attenuated without compromising mouse HDh silencing efficacy. Thus, miRNA-based approaches may provide more appropriate biological tools for expressing inhibitory RNAs in the brain, the implications of which are crucial to the development of RNAi for both basic biological and therapeutic applications.

AB - Huntington's disease (HD) is a fatal, dominant neurodegenerative disease caused by a polyglutamine repeat expansion in exon 1 of the HD gene, which encodes the huntingtin protein. We and others have shown that RNAi is a candidate therapy for HD because expression of inhibitory RNAs targeting mutant human HD transgenes improved neuropathology and behavioral deficits in HD mouse models. Here, we developed shRNAs targeting conserved sequences in human HD and mouse HD homolog (HDh) mRNAs to initiate preclinical testing in a knockin mouse model of HD. We screened 35 shRNAs in vitro and subsequently narrowed our focus to three candidates for in vivo testing. Unexpectedly, two active shRNAs induced significant neurotoxicity in mouse striatum, although HDh mRNA expression was reduced to similar levels by all three. Additionally, a control shRNA containing mismatches also induced toxicity, although it did not reduce HDh mRNA expression. Interestingly, the toxic shRNAs generated higher antisense RNA levels, compared with the nontoxic shRNA. These results demonstrate that the robust levels of antisense RNAs emerging from shRNA expression systems can be problematic in the mouse brain. Importantly, when sequences that were toxic in the context of shRNAs were placed into artificial microRNA (miRNA) expression systems, molecular and neuropathological readouts of neurotoxicity were significantly attenuated without compromising mouse HDh silencing efficacy. Thus, miRNA-based approaches may provide more appropriate biological tools for expressing inhibitory RNAs in the brain, the implications of which are crucial to the development of RNAi for both basic biological and therapeutic applications.

KW - AAV

KW - Gene therapy

KW - Huntington's disease

KW - RNAi

UR - http://www.scopus.com/inward/record.url?scp=44449121785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449121785&partnerID=8YFLogxK

U2 - 10.1073/pnas.0801775105

DO - 10.1073/pnas.0801775105

M3 - Article

C2 - 18398004

AN - SCOPUS:44449121785

VL - 105

SP - 5868

EP - 5873

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 15

ER -